PRP vs Exosome Therapy: What the Evidence Compares

Published 2 August 2026 · Updated 19 August 2026

The short answer

One trial has compared the two directly. It found no difference between them, and it tested
topical exosomes rather than injections, so it answers less than it appears to. Beyond that
trial the two treatments sit at different stages of evidence: platelet-rich plasma has years
of randomised trials behind it, with results that vary by indication and include clear
failures. Exosome therapy has promising laboratory work, a handful of small human studies and
no approved product anywhere.

That gap matters more than any comparison of mechanisms.

What each treatment actually is

PRP is your own blood. A doctor draws it, spins it in a centrifuge to
concentrate the platelets, and injects that plasma back into skin or scalp. Because the
material is autologous, there is no donor tissue and no allergy to the plasma itself. What
the platelets release once injected is the working part: growth factors that recruit the
skin’s own repair response.

Exosomes are extracellular vesicles, tiny membrane-bound packages that
cells use to send signals to other cells. They carry proteins and genetic material but contain
no living cells. The preparations used in aesthetics are allogeneic, meaning the material comes
from a source outside your body, and that is the origin of both the interest and the concern.

The one head-to-head trial, and what it does not cover

Estupiñan and colleagues ran an investigator-blinded, split-face non-inferiority trial in
photoaged facial skin, published in 2025 (doi 10.1111/jocd.70208). Participants received three
radiofrequency microneedling sessions; PRP went on one half of the face and topical
adipose-derived exosomes on the other. Both sides improved equally on wrinkling, dyschromia,
erythema, texture and overall appearance, and histology showed increased collagen I and
glycosaminoglycans with no significant difference between them.

Three limits deserve stating plainly. The exosomes were applied to the skin surface after
microneedling, not injected, so the result does not transfer to an injected exosome protocol.
Both arms sat on top of radiofrequency microneedling, which does its own work, so the trial
compares add-ons rather than standalone treatments. And a split-face design on one group of
patients with mild to moderate photoaging is a starting point, not a settled answer.

Skin: what the data shows

For PRP the picture is mixed in a useful way. A systematic review of randomised controlled
trials in dermatology covered 64 studies and 2,888 patients (doi 10.1186/s13287-024-03800-6).
In melasma a systematic review of seven studies rated the evidence a moderate grade of
recommendation on the Oxford Centre for Evidence-Based Medicine scale (doi
10.1097/DSS.0000000000003266).

Against that, a randomised single-blind study of hand rejuvenation is worth reading before
anyone promises a general anti-ageing effect: 18 women received PRP injections into one hand
and saline into the other every four weeks for twelve weeks, and a blinded investigator found
no reliable difference between the hands on any measure (doi 10.1097/PRS.0000000000011164). The
authors concluded the three-injection course was not effective for ageing skin of the hands.

For exosomes the largest skin study is a single-arm, non-randomised trial of a topical
platelet-derived exosome serum in 2022 (doi 10.1093/asj/sjac149). Skin health scores improved
significantly at six weeks. With no control group and no randomisation, that design cannot
separate the product from the skincare routine around it, which the authors do not claim it
can.

Hair: what the data shows

Androgenetic alopecia is where PRP has been studied most. In the systematic review above it
accounted for 45.3 per cent of the included trials, with improvement reported up to 68.4 per
cent depending on the study.

For exosomes, a 2025 review in Dermatologic Surgery searched three databases and found 48
studies, of which nine clinical studies were relevant to alopecia (doi
10.1097/DSS.0000000000004480). Across those, 125 patients had received an exosome treatment for
hair loss. Side effects within that group were rare. In the wider field of dermatology, though,
the same review counted at least ten serious adverse events reported with exosome products.

One hundred and twenty-five patients is a small evidence base for a treatment sold as
established. That is a statement about the literature, not about any particular clinic.

The regulatory gap

There is no approved exosome product for aesthetic use. A 2025 clinical review written for
practising dermatologists is direct about the reasons: clinical studies are lacking, and the
safety concerns include infection, unwanted inflammatory response and the theoretical promotion
of malignancy (published in the Journal of Clinical and Aesthetic Dermatology, PMID 40256340).
The hair-loss review above ends on the same point, calling for consistent manufacturing
standards and regulatory oversight.

Manufacturing is the practical part of that. Exosome preparations differ between suppliers in
how they are isolated, what concentration they contain and what else is in the vial. Two products
carrying the same word on the label are not necessarily comparable, and no independent standard
currently makes them so. Ask which preparation is being used and what documentation the clinic
holds for it.

PRP has no equivalent gap, because the material is your own blood rather than a manufactured
product. Its variability sits elsewhere: in the spin protocol, the platelet concentration
achieved and the injection technique, none of which is standardised across clinics either.

Side by side

Risks, and when neither treatment is done

Both are injectable medical procedures. Redness, small bumps and swelling at the injection
points are common, bruising can occur and is more visible around the eyes, and these typically
peak within 24 to 48 hours and settle over three to seven days. Infection at an injection point
is uncommon but possible, as is a reaction to the topical anaesthetic or antiseptic. With
exosome preparations the material is not your own, so allergic reaction is a risk that PRP does
not carry.

PRP is not performed with platelet dysfunction syndromes and other clotting conditions,
haemophilia or other bleeding disorders, during pregnancy and breastfeeding, over active
infection, inflammation, open wounds or herpes in the treatment area, during acute viral or
bacterial illness or a flare of chronic disease, with active cancer or ongoing cancer treatment,
with uncontrolled chronic, endocrine or autoimmune conditions, with severe uncontrolled diabetes
or impaired wound healing, with a keloid tendency, over severe active dermatitis, psoriasis or
neurodermatitis in the area, over active scalp infection or inflammatory scalp disease, over
suspicious skin lesions before a dermatologist has seen them, or under the age of 18.

Exosome therapy is not performed during pregnancy and breastfeeding, over active skin
infection, inflammation or herpes at the injection site, with a known allergy to the product
components, with bleeding disorders or on anticoagulant therapy without a doctor’s assessment,
with autoimmune or uncontrolled chronic conditions without the same, or with a tendency to
keloid scarring.

Neither list is exhaustive. Other conditions, medicines and previous treatments may rule a
treatment out or change the plan, and final suitability is determined by a clinician at an
in-person assessment.

How the choice is made

The question a doctor asks first is not which of the two is better but what is driving the
complaint. Thinning that follows a hormonal pattern, pigment that returns every summer and skin
that has lost firmness after weight loss are three different problems, and one of them may need
neither treatment.

Where both are reasonable, the practical differences decide. PRP needs a blood draw and
centrifugation, which lengthens the appointment and rules itself out for anyone with the
clotting conditions listed above. Exosome protocols skip the draw. Against that, PRP carries no
possibility of reaction to donor material, and its evidence base in humans is larger.

MED YU MED provides both treatments as paid services. Where the published evidence is thin,
this page says so rather than filling the gap with confidence, and where a complaint would be
better served by something the clinic does not sell, that is what a consultation should tell
you.

Cost at MED YU MED

PRP plasmotherapy starts at 800 AED, with 1,300 AED for a two-tube protocol; course and
package pricing is listed on the treatment page. Exosome therapy is 2,100 AED per session for
face and body and the same for scalp protocols, with course pricing from 5,985 AED for three
sessions. The final protocol and cost are set after consultation and depend on the area, the
number of sessions and the plan agreed with your doctor. Full details are on
the PRP treatment page and
the exosome therapy page.

If something goes wrong afterwards

Call MED YU MED on +971 52 184 5011, daily 10:00-22:00, if you develop spreading redness with
heat or pain, a fever, pus at an injection point, pain that increases rather than eases after
the first day, or a lump appearing days or weeks after a session. With any change in vision
after a facial injection, or with sudden severe pain, skin turning white or mottled, difficulty
breathing or swallowing, go to the nearest emergency department or call 998 for an ambulance
straight away. Do not wait for the clinic to reopen: it does not operate 24 hours.

Questions people ask

References

• Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus
  Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face,
  Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. doi 10.1111/jocd.70208
• Queen D, Avram MR. Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatol
  Surg. 2025;51(4):409-415. doi 10.1097/DSS.0000000000004480
• Mahmoud RH, Peterson E, Badiavas EV, Kaminer M, Eber AE. Exosomes: A Comprehensive Review for
  the Practicing Dermatologist. J Clin Aesthet Dermatol. 2025;18(4):33-40. PMID 40256340
• Proffer SL, Paradise CR, DeGrazia E, et al. Efficacy and Tolerability of Topical Platelet
  Exosomes for Skin Rejuvenation: Six-Week Results. Aesthet Surg J. 2022;42(10):1185-1193. doi
  10.1093/asj/sjac149
• Jafarzadeh A, Pour Mohammad A, Keramati H, et al. Regenerative medicine in the treatment of
  specific dermatologic disorders: a systematic review of randomized controlled clinical trials.
  Stem Cell Res Ther. 2024;15(1):176. doi 10.1186/s13287-024-03800-6
• Pincelli T, Zawawi S, Shapiro S, et al. A Pilot, Single-Blind, Randomized Controlled Study
  Evaluating the Use of Platelet-Rich Plasma for Hand Skin Rejuvenation. Plast Reconstr Surg.
  2024;154(4):727-734. doi 10.1097/PRS.0000000000011164
• Sarkar R, Gupta M. Platelet-Rich Plasma in Melasma – A Systematic Review. Dermatol Surg.
  2022;48(1):131-134. doi 10.1097/DSS.0000000000003266

Related articles

Biorevitalization Before or After a Vacation: How to Properly Prepare Your Skin for the Sun and Rescue It AfterwardBotox vs Dermal Fillers: What Each One Actually DoesMesotherapy: What It Is, and What the Evidence Supports

Medically reviewed by

DR. Alina Lebedeva

General Practitioner, Aesthetic Medicine Doctor, Dermatologist

DHA License No. 35044799-002